2018 HIV Virtual Patient: Clinical Management of Key Treatment Decisions

 

HIV_Virtual_Patien18_Web_Banner

About the Program

Program Overview

Antiretroviral therapy (ART) has evolved considerably over the past three decades. With many antiretroviral (ARV) drugs, combinations and classes available, health care providers have multiple choices regarding ARV therapy.  In recent years, significant progress has been made in the treatment of HIV, but many clinicians who manage patients infected with HIV are not aware of the full range of complex and emerging treatment options available or how to apply them to various patient scenarios. Due to the rapidly changing landscape in HIV management, this situation can significantly affect the treatment of patients with HIV infection and the quality of the care they receive, potentially affecting patient outcomes, increasing morbidity, mortality, and treatment costs.

The HIV Virtual Patient program is an interactive, case-based program featuring real-world case scenarios discussed by HIV thought leaders.  Participants will be asked to assess and treat a variety of HIV-positive and HIV-negative patient types with the direction and consultation of HIV thought leaders. This program provides important information that can be directly applied to clinical practice, thereby increasing the delivery of optimal care to patients with HIV infection in the United States.

Back to Top

Target Audience

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.

Back to Top

Learning Objectives

After completing this activity, participants should be better able to:

  • Apply in clinical practice approaches for preventing HIV infection and getting newly diagnosed patients linked to care
  • Individualize ARV therapy for the treatment-naïve and treatment-experienced patients to provide optimal ARV therapy
  • Manage HIV patients with HIV/HCV co-infection
  • Manage aging patients with HIV infection to maintain viral suppression while addressing issues associated with cardiovascular, renal, and bone disease

Release Date: April 20, 2018

Expiration Date: April 20, 2019

Estimated time to complete each Virtual Patient Case:  30-60 minutes

Back to Top

Faculty

Roberto C. Arduino, MD
Professor of Medicine
UT Director of Research
Thomas Street Clinic
The University of Texas-Houston
Houston, Texas
Richard A. Elion, MD
Associate Professor of Clinical Medicine
George Washington University Medical Center
Washington, DC
Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research
at the University of Pennsylvania
Philadelphia, Pennsylvania
Helena Kwakwa, MD, MPH
Director HIV Clinical Services
Philadelphia Department of Public Health
Ambulatory Health Services
Philadelphia, Pennsylvania
David Malebranche, MD
Associate Professor of Medicine
Morehouse School of Medicine
Atlanta, Georgia
Renslow Sherer, MD
Professor of Medicine,
Section of Infectious Diseases and Global Health
University of Chicago
Chicago, Illinois
Pablo Tebas, MD
Professor of Medicine
Hospital of the University of Pennsylvania
Director, Adult AIDS Clinical Trials Unit (ACTU)
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
Ellen Tedaldi, MD
Professor, Medicine, Lewis Katz School of Medicine at Temple University
Director, HIV Program
Temple University Hospital
Philadelphia, Pennsylvania
David A. Wohl, MD
Professor
Division of Infectious Diseases
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
 
Back to Top

Joint Accreditation Statement

Jointly-Accredited-Provider-TM_1000x636 In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Back to Top

Credit Designation

Case 1 (Treatment Experienced: Switching  Therapy):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case 2 (HIV-HCV-PWID):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case 3 (Treatment Naive: Underserved/Underinsured): 
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case 4 (Treatment Experienced: Resistance Issues):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case 5 (Treatment Naive and Asymptomatic): 
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case 6 (HIV and Aging): 
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM.
Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Back to Top

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Roberto C. Arduino, MD

  • Contracted Research: ViiV Healthcare, Inc.

Richard A. Elion, MD

  • Consulting Fees: Gilead, ViiV
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or thier agens: Gilead, Merck, Janssen

Ian Frank, MD

  • Consulting Fees: Gilead, ViiV

Helena Kwakwa, MD, MPH

  • No real or apparent conflicts to disclose

David Malebranche, MD

  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or thier agents: Gilead

Renslow Sherer, MD

  • Consulting Fees (Advisory Board): Gilead

Pablo Tebas, MD

  • Royalty: UpToDate
  • Consulting Fees: Merck, Gilead, ViiV

Ellen Tedaldi, MD

  • No real or apparent conflicts to disclose

David A. Wohl, MD

  • Consulting Fees: Gilead, ViiV, Janssen
  • Contracted Research: Gilead, ViiV(to University)

The PIM planners and managers, Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, RN, BSN and Jan Shultz, RN, MSN, CHCP have nothing to disclose.

Back to Top

Method of Participation and Request for Credit

There are no fees for participating and receiving CME/CE credit for this activity. During the period, April 20, 2018 through April 20, 2019, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 13232. Upon registering and successfully completing the activity evaluation, your certificate will be made available immediately.

Back to Top

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Back to To

Computer System Requirements:

 

This program requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable version of their content.  These activities will be marked as such and will provide links to the required software.  That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player and Real Networks Real One Player.

Back to Top

 

 

    PIM_small

    VE logo 300px 

 

This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs

 

 

Back to Top

 

     

Prepare to print

Share this page:

Get link code to this page                     


Back to Top